阿司匹林在髋膝关节置换术后VTE预防中效果不如抗凝剂
Anticoagulants Reign Supreme in VTE Prevention After Joint Replacement
一项大型比较有效性试验发现,阿司匹林在髋膝关节置换术后6个月预防静脉血栓栓塞(VTE)的主要复合终点上不如华法林和利伐沙班。阿司匹林组的事件发生率分别为1.26%,而华法林和利伐沙班分别为1.23%和0.94%。
研究对比了阿司匹林与华法林、利伐沙班在髋膝关节置换术后VTE预防中的效果,结果显示阿司匹林在主要复合终点上不如抗凝剂有效。
— Large comparative-effectiveness trial fails to find noninferiority with aspirin
November 11, 2026 • 3 min read
- Aspirin was not noninferior to warfarin or rivaroxaban for the prevention of venous thromboembolism after total hip or knee arthroplasty in a large comparative-effectiveness trial.
- Safety events -- bleeding, reoperation for wound problems, or myocardial infarction -- occurred more frequently with both anticoagulants versus aspirin, though noninferiority was not met.
- The trial was hampered by crossover from the anticoagulant groups to the aspirin group.
Aspirin didn't prevent venous thromboembolism (VTE) as well as anticoagulants did for patients undergoing elective hip or knee replacements, the randomized PEPPER trial showed.
For the primary composite endpoint of death from any cause or symptomatic VTE over 6 months after 30 days of prophylaxis, 1.26% of aspirin recipients had an event compared with 1.23% of warfarin recipients and 0.94% of rivaroxaban (Xarelto) recipients, reported Vincent Pellegrini Jr., MD, of the Geisel School of Medicine at Dartmouth in Lebanon, New Hampshire, and colleagues in the New England Journal of Medicine.
In pairwise comparisons, 6-month risks of a primary effectiveness outcome event were 1.24% and 1.01% for aspirin versus warfarin, 1.24% and 0.94% for aspirin versus rivaroxaban, and 1.13% and 1.10% for warfarin versus rivaroxaban.
The differences between aspirin and the two anticoagulants did not meet the criterion for noninferiority (P=0.09 and P=0.10), although the comparison between the two anticoagulants did (P=0.01).
Risks of a primary safety outcome event -- bleeding, reoperation for wound problems, or myocardial infarction -- were 3.65% and 2.88% for warfarin versus aspirin; 3.70% and 3.02% for rivaroxaban versus aspirin; and 3.59% and 3.61% for rivaroxaban versus warfarin, none of which met the criterion for noninferiority.
"By providing comparative risk-benefit profiles regarding thrombosis and bleeding for medications used for VTE prophylaxis, these findings can help inform preoperative decision making for patients undergoing elective total hip or knee replacement," the authors wrote.
"Aspirin is widely favored among orthopedic surgeons in the United States and Canada because of low cost, minimal bleeding risk, and the absence of required monitoring, in addition to concerns about anticoagulants with regard to increased risks of bleeding and associated wound complications, readmission, or reoperation," they noted. "However, evidence to confirm the effectiveness of aspirin as compared with anticoagulants [had been] scant."
The results might seem to contradict the findings of the EPCAT III trial published earlier this year, which showed that an aspirin-only approach was as effective and safe as rivaroxaban.
"However, at closer glance, I think they tell two parallel stories," Geoffrey Barnes, MD, of the Frankel Cardiovascular Center at the University of Michigan in Ann Arbor, told MedPage Today.
"Taken together, these two studies suggest that some component of anticoagulant therapy likely benefits patients after hip and/or knee arthroplasty surgery. As such, it might make sense to employ a short course of anticoagulation (e.g., rivaroxaban 10 mg daily for 5 days) followed by aspirin therapy in most hip and knee surgery patients at average risk of postoperative VTE," he argued.
Pellegrini and team noted that EPCAT III and another trial comparing 5 days of rivaroxaban then aspirin versus rivaroxaban alone were much smaller and both had larger noninferiority margins that were equal to the entire projected incidence of VTE and excluded patients at high risk for VTE.
The PEPPER trial randomly assigned patients at 34 centers in the U.S. and Canada who were undergoing elective hip or knee arthroplasty for osteoarthritis to receive open-label treatment with aspirin (81 mg twice daily), warfarin (to a target international normalized ratio of 2.0), or rivaroxaban (10 mg daily) for 30 days.
VTE made up most of the events in the primary effectiveness endpoint. The noninferiority margin for the risk difference in the primary composite effectiveness outcome measure was 0.69 percentage points. Intention-to-treat analyses yielded similar results to those of the per-protocol analysis.
The trial included 15,317 patients in the primary per-protocol analysis: 7,214 with hip arthroplasty and 8,103 with knee arthroplasty. However, a "very large number of patients [more than 3,500] were excluded from both the warfarin and rivaroxaban groups because of crossover and an inability to stay on the assigned drug," Barnes noted. "While measured covariates were balanced across all three groups, this large difference in exclusions may have introduced unmeasured confounding."
Cost and monitoring affected adherence to rivaroxaban and warfarin, respectively, such that fewer patients crossed over from the aspirin group. Indeed, the per-protocol aspirin cohort (6,090 participants) was 22% larger than the rivaroxaban cohort (4,996 participants) and was 44% larger than the warfarin cohort (4,231 participants), "despite similar initial randomization numbers," Pellegrini and team acknowledged.
The researchers agreed that the crossovers compromised the benefits of randomization "but reflect the pragmatic comparative-effectiveness design."
来源:MedPage Today · medpagetoday.com